Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tomasz Wojtkowski"'
Autor:
Srinivasu Poondru, Vitalii Ghicavii, Reza Khosravan, Pooja Manchandani, Nakyo Heo, Selina Moy, Tomasz Wojtkowski, Melanie Patton, Gabriel P. Haas
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 5, Pp 1131-1142 (2022)
Abstract Drug‐drug interaction (DDI) is an important consideration for clinical decision making in prostate cancer treatment. The objective of this study was to evaluate the effect of enzalutamide, an oral androgen receptor inhibitor, on the pharma
Externí odkaz:
https://doaj.org/article/cc204e83d67f46e2a224c3bb586df58b
Autor:
Yuta Taniuchi, J. W. Olivier van Till, Tomasz Wojtkowski, Junko Toyoshima, Akira Koibuchi, Briana Sargent, David Han
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c64cfacd6167d4452e3112e56977b414
https://doi.org/10.1002/cpdd.1236
https://doi.org/10.1002/cpdd.1236
Autor:
Mototsugu Ito, Tomasz Wojtkowski, Ronald A. Smulders, Akihiro Yamada, Ronald Goldwater, Akira Koibuchi, Tolga Uz, Sitra Tauscher-Wisniewski, Gerard J. Marek
Publikováno v:
Muscle & Nerve. 65:110-120
Introduction/aims ASP0367, or bocidelpar sulfate, is an orally administered small molecule that potently and selectively modulates peroxisome proliferator-activated receptor δ (PPARδ) to address mitochondrial dysfunction occurring in diseases inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbdea70432c6f16acb2f20525a7f7d76
https://doi.org/10.1002/mus.27436
https://doi.org/10.1002/mus.27436
Autor:
Mototsugu, Ito, Sitra, Tauscher-Wisniewski, Ronald A, Smulders, Tomasz, Wojtkowski, Akihiro, Yamada, Akira, Koibuchi, Tolga, Uz, Gerard J, Marek, Ronald D, Goldwater
Publikováno v:
Musclenerve. 65(1)
ASP0367, or bocidelpar sulfate, is an orally administered small molecule that potently and selectively modulates peroxisome proliferator-activated receptor δ (PPARδ) to address mitochondrial dysfunction occurring in diseases including primary mitoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f6f14c70caeea1680b01d375a878d446
https://pubmed.ncbi.nlm.nih.gov/34642949
https://pubmed.ncbi.nlm.nih.gov/34642949
Autor:
Jay P. Garg, Ogert Fisniku, David Han, Tomasz Wojtkowski, Corrie Howieson, Tong Zhu, James Keirns
Publikováno v:
Clinical Pharmacology in Drug Development. 6:548-555
Peficitinib is an orally administered, once-daily Janus kinase inhibitor currently in development for the treatment of rheumatoid arthritis. It has been shown to be a P-glycoprotein (P-gp) substrate in vitro. The effects of verapamil, an inhibitor of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::271d3cd47d9f84a525bfc81cd5d1fc1c
https://doi.org/10.1002/cpdd.344
https://doi.org/10.1002/cpdd.344
Autor:
Peter R. Kowey, Takao Yamazaki, Mark Yen, Salim Mujais, Christopher Lademacher, Amit Desai, Tomasz Wojtkowski, B Parker, Robert Townsend, Donna Kowalski, James Keirns, Marlowe J. Schneidkraut
Publikováno v:
Clinical Pharmacology and Therapeutics
The effects of isavuconazole (active moiety of isavuconazonium sulfate) on cardiac ion channels in vitro and cardiac repolarization clinically were assessed in a phase I, randomized, double‐blind study in healthy individuals who received isavuconaz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e55044171cfe9344ae884a245a4014bc
https://doi.org/10.1002/cpt.620
https://doi.org/10.1002/cpt.620
Autor:
Amit Desai, Keun-Wook Lee, Tomasz Wojtkowski, Yoko Ueno, Jung Wook Park, Yung-Jue Bang, Kohei Shitara, Fotios Loupakis, Janet Pavese, Jianning Yang, Akihiro Yamada, Samuel J. Klempner
Publikováno v:
Journal of Clinical Oncology. 39:e16078-e16078
e16078 Background: Zolbetuximab is a chimeric IgG1 monoclonal antibody that targets Claudin 18.2 (CLDN18.2), a tight junction protein that is normally confined to gastric mucosa but is retained in G/GEJ. A phase 2 (NCT01630083, FAST) trial demonstrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf97e5d81187bdc297ff1d573650b47a
https://doi.org/10.1200/jco.2021.39.15_suppl.e16078
https://doi.org/10.1200/jco.2021.39.15_suppl.e16078
Autor:
Hiroyuki Oshima, Ingrid Michon, Tomasz Wojtkowski, Takao Yamazaki, Salim Mujais, Atsunori Kaibara, Lauren Benner, Takashi Miki
Publikováno v:
Clinical Drug Investigation
Background and Objectives Fidaxomicin treatment of Clostridium difficile infection is known to produce minimal systemic exposure, as the antibacterial (antibiotic) remains primarily in the gut. In this randomized, double-blind, placebo-controlled stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56d0d80a8e6a948162334a04abf81a53
http://europepmc.org/articles/PMC4449367
http://europepmc.org/articles/PMC4449367
Autor:
Tomasz Wojtkowski, Tetsuya Nishimura, David Han, Tong Zhu, Ogert Fisniku, Barbara Parker, Jay P. Garg, James Keirns
Publikováno v:
Clinical pharmacokinetics. 56(7)
Peficitinib is an orally administered, once-daily Janus kinase inhibitor in development for the treatment of rheumatoid arthritis. Peficitinib and its major metabolite H2 inhibit the hepatic uptake transporter organic anion transporting polypeptide 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::997895a47cd65d8292d7912f141047c7
https://pubmed.ncbi.nlm.nih.gov/27878567
https://pubmed.ncbi.nlm.nih.gov/27878567